Medicare AdvantageCoverageMedium impact
MA08.174, Secukinumab (Cosentyx®) for Intravenous Use
Independence Blue Cross·Rheumatology, Dermatology·Pharmacy
Effective date
May 27, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.174 for Secukinumab (Cosentyx®) intravenous use has been reissued and will be effective May 27, 2026. This is a pharmacy policy update that may affect coverage criteria or administration requirements for this biologic medication used primarily in rheumatology and dermatology.
Action Required
Before May 27, 2026: Billing team should review the full policy details at the provided URL to understand specific coverage changes for Secukinumab (Cosentyx®) IV administration. Update prior authorization procedures and billing protocols as outlined in the complete policy. Notify providers who prescribe biologics for rheumatologic and dermatologic conditions of any coverage requirement changes.